Barach Family Trust Secures Board Control and Expanded Convertible Financing Terms
CELU has more than doubled off its 52-week low of $0.56.
Summary
The Barach Family Trust disclosed a $3.21 million convertible note purchase with board designation rights, an option for $2.9 million more, and repricing of existing securities — cementing insider control over Celularity.
Key Events · Ownership and Investor Activity · CELU
-
Board Rights Agreement Grants Two Seats
The Trust can designate two of five board seats, with Philip Barach appointed as a Trust Director on September 24, 2026. Spending of financing proceeds is restricted until the board is fully composed.
-
Option for $2.9M Additional Investment
The Trust holds an option through September 30, 2027 to purchase up to $2,915,531 of additional convertible notes at a $2.00 conversion price, with up to 1,457,765 warrants at $2.00 exercise price.
-
Existing Securities Repriced Lower
The December 2025 convertible note conversion price was reduced from $1.66 to $1.50, and warrants were repriced from $2.00 to $1.50, increasing the Trust's potential share count to 9,491,270 shares (24.5% of outstanding).
-
Registration Rights Required
The Company must file a registration statement covering the Trust's securities within 45 days and have it effective within 90-120 days, making the shares tradable.
Analysis · CELU · Life Sciences
Philip Barach and his family trust have deepened their control over Celularity through a $3.21 million convertible note purchase that comes with significant governance rights. The Board Rights Agreement fixes the board at five directors and gives the Trust the right to designate two seats, with Philip Barach already appointed. The Trust also holds an option to invest up to $2.9 million more through September 2027 at a $2.00 conversion price. Existing December 2025 notes and warrants were repriced from $1.66/$2.00 down to $1.50, increasing the Trust's potential share count. This is a major power shift for a company that has faced Nasdaq delisting notices and leadership turmoil.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.2M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.